Genome-wide CRISPR-Cas9 screens identify mechanisms of BET bromodomain inhibitor sensitivity

Genome-wide CRISPR-Cas9 screens identify mechanisms of BET bromodomain inhibitor sensitivity

Summary: BET bromodomain inhibitors hold promise as therapeutic agents in diverse indications, but their clinical progression has been challenging and none have received regulatory approval. Early clinical trials in cancer have shown heterogeneous clinical responses, development of resistance, and a...

Full description

Bibliographic Details
Main Authors: David Estoppey, Gabi Schutzius, Christian Kolter, Adrian Salathe, Tiffany Wunderlin, Amandine Meyer, Florian Nigsch, Tewis Bouwmeester, Dominic Hoepfner, Susan Kirkland
Format: Article
Language:English
Published: Elsevier 2021-11-01
Series:iScience
Subjects:
Molecular biology
Cell biology
Chemogenomics
Online Access:http://www.sciencedirect.com/science/article/pii/S258900422101292X

Internet

http://www.sciencedirect.com/science/article/pii/S258900422101292X

Similar Items